
簡要描述:Clevidipine butyrate 167221-71-8Cleviprex (Clevidipine) is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hy
產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
| 品牌 | absin | CAS | 167221-71-8 |
|---|---|---|---|
| 分子式 | C21H23Cl2NO6 | 純度 | 99% |
| 分子量 | 456.32 | 貨號 | abs47027439 |
| 規(guī)格 | 10mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is a short-acting dihydropyridine calciu | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Clevidipine butyrate 167221-71-8
| 產(chǎn)品描述 | |
| 描述 | Cleviprex (Clevidipine) is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension. |
| 純度 | 99% |
| 儲存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 可溶性/溶解性 | DMSO 91 mg/mL;Ethanol 3 mg/mL; |
| 參考文獻 | |
| 參考文獻 |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Cardiovascular CancerCancer Metabolism Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
